Plus   Neg

Ligand Pharma Raises 2018 Financial Guidance - Quick Facts

Ligand Pharmaceuticals Incorporated (LGND) raised its previous guidance for 2018 and now expects revenue to be approximately $240 million, including royalties of approximately $122 million, material sales of approximately $25 million and license fees and milestones of approximately $93 million, with the potential for up to an additional $5 million in license fees and milestones. Ligand projects adjusted earnings per diluted share would be approximately $6.52. The company's previous guidance was revenue of approximately $232 million, and adjusted earnings per diluted share of approximately $6.30.

Adjusted net income for the third quarter of 2018 was $31.7 million, or $1.32 per diluted share, compared with $15.3 million, or $0.69 per diluted share, for the same period in 2017. Total revenues were $45.7 million, compared with $33.4 million for the same period in 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following the sell-off seen in the previous session, stocks showed another significant move to the downside during trading on Tuesday. With the continued drop, the tech-heavy Nasdaq fell to its lowest closing level in over seven months. A federal judge in San Francisco has temporarily blocked President Donald Trump's plan to restrict asylum claims by illegal immigrants. In a ruling issued late Monday, U.S. District Court Judge Jon Tigar accused the Trump administration of trying to rewrite immigration laws. Bank of England Governor Mark Carney welcomed the draft Brexit deal and the transition arrangement that the British Prime Minister Theresa May struck with the European Union last week, but warned that the risks of a "no-deal, no-transition" scenario remained very high. Speaking at a Treasury Select Committee hearing, Carney said, "We welcome the transition arrangements in the withdrawal deal."
Follow RTT